{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0935254"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"139"}],"units":"Participants"}],"description":"Proportion of participants in complete remission by morphology and with positive MRD by flow cytometry among patients having evaluable remission and MRD assessment.","groups":[{"description":"INDUCTION THERAPY COURSE I: Patients receive cytarabine IT on day 1 and cytarabine IV continuously over 96 hours, daunorubicin hydrochloride IV continuously, and oral thioguanine BID on days 1-4.\n\nCOURSE II: Patients receive high-dose cytarabine IV over 3 hours BID on days 1, 2, 8, and 9 and asparaginase (IM) on days 2 and 9.\n\nCOURSE III: Patients receive treatment as in course I. COURSE IV: Patients receive cytarabine IV, daunorubicin hydrochloride IV, and oral thioguanine as in course I INTENSIFICATION THERAPY: Patients receive cytarabine IV continuously over 168 hours on days 1-7 and etoposide IV over 1 hour on days 1-3. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity.\n\nasparaginase: Given IM daunorubicin hydrochloride: Given IV cytarabine: Given IV or IT thioguanine: Given orally etoposide: Given IV laboratory biomarker analysis: Correlative studies","id":"OG000","title":"Treatment (Combination Chemotherapy)"}],"paramType":"NUMBER","populationDescription":"Ineligible patients (n=1) are excluded. Patients without available MRD at end of Induction I (n=58) or not evaluable for morphologic remission assessment (n=7) are excluded. MRD data are not available at end of Induction IV or after completion of Intensification therapy.","reportingStatus":"POSTED","timeFrame":"After Induction I therapy (day 28 from start of therapy)","title":"Proportions of Patients in Morphologic Remission With Positive MRD by Flow Cytometry","type":"SECONDARY","unitOfMeasure":"Proportion of participants"}